Department of Gastroenterology, Huaihe Hospital of Henan University, 475000, China.
Department of General Surgery, Huaihe Hospital of Henan University, 475000, China.
Biomed Pharmacother. 2017 Dec;96:953-959. doi: 10.1016/j.biopha.2017.11.145. Epub 2017 Dec 6.
Emerging evidences have proved that long non-coding RNAs (lncRNAs) act as important molecular regulator in the tumor progression, including colorectal cancer (CRC). LncRNA SOX21-AS1 has been verified as oncogenic molecular in other cancers and tumorigenesis. In present study, our team investigates the clinical characteristic and molecular function in CRC carcinogenesis. Results showed that lncRNA SOX21-AS1 expression was significantly over-expressed in CRC tissue samples and cells. The aberrant over-expression of SOX21-AS1 indicated poor prognosis of CRC patients. In vitro and in vivo validation experiments, SOX21-AS1 silencing inhibited the proliferation, invasion, and decreased the tumor growth of CRC cells. Moreover, miR-145 was proved to be the target of SOX21-AS1, besides, myosin VI (MYO6) was found to be one of the targets of miR-145 using bioinformatics prediction programs and rescue confirmation experiments. In summary, our study reveals the tumorigenic effect of lncRNA SOX21-AS1 in CRC cells via targeting miR-145/MYO6, providing a novel insight for CRC carcinogenesis.
越来越多的证据表明，长非编码 RNA（lncRNA）在肿瘤进展中作为重要的分子调节剂发挥作用，包括结直肠癌（CRC）。LncRNA SOX21-AS1 在其他癌症和肿瘤发生中已被证实为致癌分子。在本研究中，我们的团队研究了 lncRNA SOX21-AS1 在 CRC 发生中的临床特征和分子功能。结果表明，lncRNA SOX21-AS1 在 CRC 组织样本和细胞中表达明显过表达。SOX21-AS1 的异常过表达表明 CRC 患者的预后不良。体外和体内验证实验表明，沉默 SOX21-AS1 抑制 CRC 细胞的增殖、侵袭，并降低肿瘤生长。此外，通过生物信息学预测程序和挽救确认实验证实，miR-145 是 SOX21-AS1 的靶标之一，而肌球蛋白 VI（MYO6）则是 miR-145 的靶标之一。综上所述，我们的研究通过靶向 miR-145/MYO6 揭示了 lncRNA SOX21-AS1 在 CRC 细胞中的致瘤作用，为 CRC 发生提供了新的见解。
